The distinct co-expression pattern of PD-L1 and CD47 in cancers compared to normal tissues provides a rationale for designing BsAbs that can selectively recognize PD-L1+CD47+ tumor cells and block their CD47 signaling to trigger the engulfment of double-positive cancer cells. Here, CD47 is linked to neoplasm.